Too often, recruiters are more clear on what a position will “do” rather than what it will “achieve”.Outlining tasks and responsibilities takes priority over goals and impact.But to attract top talent, you need to define and explain what success looks…
HOME > BUSINESS
BUSINESS
- Oncolys, NCC Hospital East to Run Investigator-Led Trial on Oncolytic Virus
August 15, 2016
- AnGes MG, Vical to Form Biz Tie-Up over DNA Vaccines
August 15, 2016
- Shionogi Begins Distribution of Ethical Isodine Products: Mundipharma
August 15, 2016
- Teijin Gets Japan Rights to Versartis’ Growth Hormone Deficiency Treatment
August 15, 2016
- JT/Torii License Menlo’s Pruritus Candidate for Japan Market
August 15, 2016
- Sawai Eyes First-to-File Status for 5 Generics in the US
August 10, 2016
- Japan PII Now Underway for Otsuka’s DMD Candidate TAS-205
August 10, 2016
- Otsuka Suffers Big Drops in Pharma Sales, Profit on US Abilify Patent Loss
August 10, 2016
- Astellas Files Japan NDA for Quetiapine for Bipolar Disorder
August 10, 2016
- Kissei, JCR Kick Off Japan PIII for Nesp Biosimilar
August 10, 2016
- Eisai, Biogen to Launch Global PIII for Alzheimer’s Drug by March-End
August 10, 2016
- Ono Rushes to Soothe Investor Nerves over Opdivo PIII Data
August 10, 2016
- Opdivo Disappoints in 1st-Line Lung Cancer Trial
August 9, 2016
- Carna Biosciences, Janssen Call Off Licensing Deal for Kinase Inhibitor
August 8, 2016
- Takeda, Pfizer to Wind Up Sales Deal for Prevenar, BeneFIX
August 8, 2016
- Meiji Seika Pharma Licenses Therapeutic Candidate Substance for Multiple Sclerosis to Curadim Pharma
August 8, 2016
- Astellas to Transfer US Manufacturing Unit to Avara
August 5, 2016
- Sumitomo Dainippon to Nurture Specialized Reps as It Pushes Oncology, Other Biz Focus
August 5, 2016
- Rohto, Osaka Univ. Tie Up for Stem Cell Research, Aim for Approval of Regenerative Medicine Products
August 5, 2016
- Zafatek Most Heavily Promoted Drug in GP Market in June: Anterio
August 4, 2016
ページ
Pharmaceutical companies are giving high marks to Japan’s drug pricing reform for FY2024. According to a survey conducted by Jiho, 51% of all respondents expressed a positive opinion of the reform, saying that they were “somewhat satisfied” with it. The…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…